MOLLENHAUER, Brit, Lucilla PARNETTI, Irena REKTOROVÁ, Milica G. KRAMBERGER, Maria PIKKARAINEN, Walter J. SCHULZ-SCHAEFFER, Dag AARSLAND, Per SVENNINGSSON, Lucia FAROTTI, Marcel M. VERBEEK a Michael G. SCHLOSSMACHER. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. Journal of Neurochemistry. HOBOKEN: WILEY-BLACKWELL, 2016, roč. 139, October, s. 290-317. ISSN 0022-3042. Dostupné z: https://dx.doi.org/10.1111/jnc.13390.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders
Autoři MOLLENHAUER, Brit (276 Německo), Lucilla PARNETTI (380 Itálie), Irena REKTOROVÁ (203 Česká republika, garant, domácí), Milica G. KRAMBERGER (705 Slovinsko), Maria PIKKARAINEN (246 Finsko), Walter J. SCHULZ-SCHAEFFER (276 Německo), Dag AARSLAND (752 Švédsko), Per SVENNINGSSON (752 Švédsko), Lucia FAROTTI (380 Itálie), Marcel M. VERBEEK (528 Nizozemské království) a Michael G. SCHLOSSMACHER (124 Kanada).
Vydání Journal of Neurochemistry, HOBOKEN, WILEY-BLACKWELL, 2016, 0022-3042.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30000 3. Medical and Health Sciences
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 4.083
Kód RIV RIV/00216224:14740/16:00092576
Organizační jednotka Středoevropský technologický institut
Doi http://dx.doi.org/10.1111/jnc.13390
UT WoS 000385770500019
Klíčová slova anglicky cerebrospinal fluid biomarker; confounding; factors; dementia; neuropathology; Parkinson's disease; -synuclein; -amyloid; tau-protein
Štítky rivok
Změnil Změnila: Mgr. Eva Špillingová, učo 110713. Změněno: 2. 1. 2017 13:54.
Anotace
Cerebrospinal fluid (CSF) has been extensively studied to explore biochemical alterations in subjects with neurodegenerative disorders. In Alzheimer's disease, levels of increased CSF tau protein and decreased levels of -amyloid 1-42 (A42) have been shown to correlate with brain plaque formation and tangle pathology. Intracellular Lewy inclusions containing aggregated -synuclein (-syn) represent a pathological hallmark of Parkinson's disease (PD). In most - but not all - studies published to date total CSF -syn concentrations have been found to be decreased in disorders related to -syn pathology, that is, PD, dementia with Lewy bodies and multiple system atrophy. However, these reports show extensive signal overlap among tested individuals, thereby diminishing its potential for routine use in clinical practice. To investigate potential biological (i.e., non-technical) confounders of reported CSF levels for -syn, A42, and tau in PD and related disorders, we carried out a methodical review of known factors that underlie signal variability and speculate on those that have not yet been tested. We discuss several biological factors, such as neuropathology, demographics, clinical phenotype, progression and duration of disease, concomitant illnesses and, last but not least, pharmacotherapy, which in isolation or combination can substantially alter values for CSF proteins of interest. Enhanced implementation of standardized clinical protocols, streamlined operating procedures, and further progress in the development of validated assays for CSF proteins have the potential to (i) inform us as to the pathogenesis of disease, (ii) support the laboratory-based diagnosis for symptomatic subjects in the future, and (iii) facilitate breakthrough therapies to alter the course of neurodegenerative disorders, such as PD and Alzheimer's disease. Cerebrospinal fluid (CSF) has been extensively studied to explore biochemical alterations in subjects with neurodegenerative disorders. To investigate potential biological confounders of reported CSF levels for -synuclein (-Syn), amyloid- 1-42(A42) and tau protein in Parkinson's disease and related disorders, we reviewed the current literature for known factors that underlie signal variability and speculate on those that have not yet been tested. This article is part of a .
Návaznosti
ED1.1.00/02.0068, projekt VaVNázev: CEITEC - central european institute of technology
VytisknoutZobrazeno: 26. 4. 2024 13:33